Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Georgia E. Ritchie
Observed names:
G Ritchie,
G. Ritchie,
Georgia Ritchie
Institution:
Medical Oncology Group of Australia
Observed institutions:
The University of Sydney,
UNSW Sydney,
Prince of Wales Hospital,
The George Institute for Global Health,
St George Hospital,
Port Macquarie Base Hospital,
Medical Oncology Group of Australia,
Imperial College London
show all 8
OpenAlex ID:
A5111644641
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis
2018
·
Georgia Ritchie
, Harry Gasper
, et al.
·
JAMA Oncology
·
126
PDF
Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis
2020
·
Peey-Sei Kok
, Doah Cho
, et al.
·
JAMA Network Open
·
56
PDF
Treatment‐related toxicities of immune checkpoint inhibitors in advanced cancers: A meta‐analysis
2018
·
Johnathan Man
, Georgia Ritchie
, et al.
·
Asia-Pacific Journal of Clinical Oncology
·
49
Comparison of Near-Patient Capillary Glucose Measurement and a Risk Assessment Questionnaire in Screening for Type 2 Diabetes in a High-Risk Population in Rural India
2010
·
Georgia E. Ritchie
, Andre Pascal Kengne
, et al.
·
Diabetes Care
·
33
PDF
Effectiveness of intermediate care in nursing-led in-patient units
2004
·
PD Griffiths
, MH Edwards
, et al.
·
Cochrane Database of Systematic Reviews
·
28
Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review
2016
·
Georgia E. Ritchie
, Mangalee Fernando
, et al.
·
Cancer Chemotherapy and Pharmacology
·
20
Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?
2017
·
G. Ritchie
, H. Gasper
, et al.
·
Annals of Oncology
·
4
PDF
Repurpose: Phase Ii Study Assessing the Efficacy of Efavirenz, an Approved Hiv Drug Repurposed as an Anti-cancer Agent, in Patients With Platinum Resistant Ovarian Cancer
2025
·
Janine Lombard
, Alison Davis
, et al.
·
International Journal of Gynecological Cancer
·
1
2087P Efficacy and safety of ATG-037, an oral CD73 inhibitor, plus pembrolizumab in patients with checkpoint inhibitor (CPI) resistant melanoma: Updated results from the STAMINA-01 trial
2026
·
L. Mao
, L. Si
, et al.
·
Annals of Oncology
CAPTURE: A phase II trial evaluating alpelisib + fulvestrant vs capecitabine in advanced breast cancer patients with PIK3CA -mutant circulating DNA following CDK4/6 inhibition.
2026
·
Eileen Geoghegan
, Ankit K. Dutta
, et al.
·
Journal of Clinical Oncology
Reply to Q. Wu et al.
2019
·
Johnathan Man
, Georgia Ritchie
, et al.
·
Asia-Pacific Journal of Clinical Oncology
A systematic review of the safety and efficacy of parenteral estrogens in prostate cancer
2005
·
R. Langley
, G. Norman
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
12
Citation count:
317
H-index:
6
I10-index:
6
Year
Topic
Type